NEU 3.17% $1.38 neuren pharmaceuticals limited


  1. 2,085 Posts.
    lightbulb Created with Sketch. 24

    AIC2015: Showcasing Investment Opportunities in Autism Treatment, Assessment & Technology

    Autism Speaks announces preliminary lineup of presenters for 2015 Autism Investment Conference, March 10-11: Showcase Sessions on autism therapeutics, assessment and assistive technology
    February 09, 2015

    About half way down is:

    Larry Glass, chief executive officer of Neuren Pharmaceuticals, will showcase Neuren’s strategy for developing their lead compound, “NNZ-2566,” for the treatment of neurodevelopmental syndromes. Neuren is developing a number of new treatment for brain disorders and conditions, including autism, Rett syndrome and fragile X syndrome.
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Mkt cap $151.4M
Open High Low Value Volume
$1.40 $1.42 $1.38 $38.00K 27.39K

Buyers (Bids)

No. Vol. Price($)
1 2500 $1.38

Sellers (Offers)

Price($) Vol. No.
$1.43 2272 1
Last update - 15.27pm 17/01/2019 (20 minute delay) ?
-0.05 ( 1.42 %)
Open High   Low Volume
$1.39 $1.39   $1.39 908
Last updated 14.04pm 17/01/2019 (live) ?
NEU (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.